Use of hCG in controlled ovarian hyperstimulation
AssigneeLaboratories Serono SA
InventorYves Menezo
Life of this patent
Estimating the term…
Abstract
The invention provides a protocol leading to improved embryo implantation rates and/or decreased miscarriage rates in which hCG, or a bio-analogue, is administered during the follicular phase.
Claims15
A method for aiding implantation and/or decreasing miscarriage rates, comprising administering to a patient in need thereof one or more low doses of human chorionic gonadotropin (hCG), or an analogue thereof, during controlled ovarian hyperstimulation (COH) in human patients but before ovulation or ovulation triggering, wherein the hCG or an analogue thereof is administered starting between the 3rd and 10th day after commencing treatment with FSH, an analogue thereof, or a compound that stimulates endogenous FSH secretion.
Dependencies are inferred from the claim text.